[SPS 2022 ADME] Integrated Cardiac Proarrhythmic Risk Assessment Using Human-Induced Pluripotent Stem Cell (hiPSC)-Derived Cardiomyocytes

[SPS 2022 ADME] Integrated Cardiac Proarrhythmic Risk Assessment Using Human-Induced Pluripotent Stem Cell (hiPSC)-Derived Cardiomyocytes
Version:
21369

File Name/Number:
SPS

Year:
2022

 

The Comprehensive in vitro Proarrhythmia Assay (CiPA) initiative is an effort to improve the accuracy of proarrhythmic risk assessment by reducing the focus on in vitro hERG channel assays and in vivo QT interval measurements.